Lichenoid drug eruption on the lower lip caused by anti-PD-1 monoclonal antibody: a case report and literature review

被引:6
作者
Kan, Siyue [1 ]
Ren, Hongjin [1 ]
Gao, Zhiqin [1 ]
Dai, Erhong [1 ]
Liu, Yeqiang [2 ]
Yang, Lianjuan [1 ]
Cai, Qing [1 ]
机构
[1] Tongji Univ, Sch Med, Dept Med Mycol, Shanghai Skin Dis Hosp, Shanghai 200443, Peoples R China
[2] Tongji Univ, Sch Med, Dept Pathol, Shanghai Skin Dis Hosp, Shanghai 200443, Peoples R China
关键词
anti-PD-1; PD-L1; corticosteroid therapy; He-Ne laser; immune checkpoint inhibitors; immune-related adverse events; oral lichenoid drug reactions; prostate carcinoma; toripalimab;
D O I
10.2217/imt-2021-0234
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anti-PD-1/PD-L1 monoclonal antibodies result in a unique spectrum of side effects, widely known as immune-related adverse events. Toripalimab is an anti-PD-1 monoclonal antibody used for the treatment of some cancers. Here we report the first case, to our knowledge, of oral lichenoid drug reaction triggered by toripalimab. A 78-year-old man who was diagnosed with systemic metastatic prostate cancer presented with ulcers on the lower lip after the fifth cycle of toripalimab. We diagnosed him with oral lichenoid drug reaction based on clinical manifestation, histopathological findings and the history of anti-PD-1 therapy. The patient responded well to oral corticosteroids combined with helium-neon laser therapy. The anti-PD-1 therapy was not restarted because of stable disease, and the eruptions did not recur.
引用
收藏
页码:1373 / 1378
页数:6
相关论文
共 16 条
  • [1] Drug-induced oral lichenoid reaction during nivolumab therapy
    Enomoto, Y.
    Nakatani, H.
    Kondo, S.
    Kasai, T.
    Tsuchiya, Y.
    [J]. INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2019, 48 (04) : 488 - 491
  • [2] The effect of He-Ne and Ga-Al-As laser light on the healing of hard palate mucosa of mice
    Fahimipour, Farahnaz
    Mahdian, Mina
    Houshmand, Behzad
    Asnaashari, Mohammad
    Sadrabadi, Alireza Naser
    Farashah, Seid Emadadin Najafi
    Mousavifard, Seid Mohsen
    Khojasteh, Arash
    [J]. LASERS IN MEDICAL SCIENCE, 2013, 28 (01) : 93 - 100
  • [3] Cutaneous Adverse Reactions of Anticancer Agents
    Kaul, Subuhi
    Kaffenberger, Benjamin H.
    Choi, Jennifer N.
    Kwatra, Shawn G.
    [J]. DERMATOLOGIC CLINICS, 2019, 37 (04) : 555 - +
  • [4] Toripalimab: First Global Approval
    Keam, Susan J.
    [J]. DRUGS, 2019, 79 (05) : 573 - 578
  • [5] Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
    Lacouture, Mario
    Sibaud, Vincent
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 : 31 - 39
  • [6] Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes
    Melanie, Claps
    Alessia, Mennitto
    Valentina, Guadalupi
    Pierangela, Sepe
    Marco, Stellato
    Emma, Zattarin
    Silke, Gillessen Sommer
    Cora, Sternberg N.
    Alfredo, Berruti
    Maria, De Braud Filippo Guglielmo
    Elena, Verzoni
    Giuseppe, Procopio
    [J]. CANCER TREATMENT REVIEWS, 2020, 88
  • [7] Severe Oral Ulcers Associated With Nivolumab Treatment
    Namiki, Takeshi
    Hanafusa, Takaaki
    Ueno, Makiko
    Miura, Keiko
    Yokozeki, Hiroo
    [J]. JAMA DERMATOLOGY, 2017, 153 (02) : 235 - 237
  • [8] National Institutes of Health NCI, 2017, COMMON TERMINOLOGY C
  • [9] Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review
    Obara, Koya
    Masuzawa, Mamiko
    Amoh, Yasuyuki
    [J]. JOURNAL OF DERMATOLOGY, 2018, 45 (05) : 587 - 591
  • [10] Is There a Role for Immunotherapy in Prostate Cancer?
    Rizzo, Alessandro
    Mollica, Veronica
    Cimadamore, Alessia
    Santoni, Matteo
    Scarpelli, Marina
    Giunchi, Francesca
    Cheng, Liang
    Lopez-Beltran, Antonio
    Fiorentino, Michelangelo
    Montironi, Rodolfo
    Massari, Francesco
    [J]. CELLS, 2020, 9 (09) : 1 - 24